Analyzing Cost of Revenue: Novartis AG and Xenon Pharmaceuticals Inc.

Cost of Revenue Trends: Novartis vs. Xenon (2014-2023)

__timestampNovartis AGXenon Pharmaceuticals Inc.
Wednesday, January 1, 2014173450000005903000
Thursday, January 1, 2015174040000002762000
Friday, January 1, 2016175200000001114000
Sunday, January 1, 20171717500000025573000
Monday, January 1, 2018184070000006000000
Tuesday, January 1, 20191442500000038845000
Wednesday, January 1, 20201512100000050523000
Friday, January 1, 20211586700000075463000
Saturday, January 1, 202215486000000105767000
Sunday, January 1, 202312472000000167512000
Monday, January 1, 202412827000000
Loading chart...

Unveiling the hidden dimensions of data

Analyzing Cost of Revenue: Novartis AG vs. Xenon Pharmaceuticals Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for strategic planning. This analysis delves into the cost of revenue trends for Novartis AG and Xenon Pharmaceuticals Inc. from 2014 to 2023. Novartis AG, a global healthcare leader, consistently reported a high cost of revenue, peaking in 2018 with a 14% increase from 2017. However, a notable decline of 32% was observed by 2023, reflecting strategic shifts or market challenges. In contrast, Xenon Pharmaceuticals Inc., a smaller player, showed a dramatic rise in cost of revenue, surging over 2800% from 2014 to 2023. This growth trajectory highlights Xenon's expanding operations and market presence. The contrasting trends between these companies underscore the diverse strategies and market dynamics within the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025